{'fraction_non_alphanumeric': 0.01837270341207349, 'fraction_numerical': 0.010498687664041995, 'mean_word_length': 5.692982456140351, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lucentis offers treatment alternative for diabetic retinopathy, trial finds

The drug ranibizumab (Lucentis) injected into the eye seems to be an effective alternative treatment for proliferative diabetic retinopathy when compared with the standard laser therapy, a multicentre randomised trial published in JAMA has found.1

The laser treatment, panretinal photocoagulation, is the standard treatment for reducing severe visual loss from diabetic retinopathy. However, the treatment can cause permanent peripheral visual field loss and decreased night vision and may exacerbate diabetic macular oedema.

The non-inferiority study included 305 adults with proliferative diabetic retinopathy at 55 sites in the United States. Of these patients, 89 had both eyes …